Vaxin enrolls first patient in Phase I trial of HepTcell to treat hepatitis B virus
HepTcell is a peptide-based immunotherapeutic which includes the company’s proprietary Densigen technology. The product candidate includes nine long peptides covering conserved regions of core, polymerase and surface proteins
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.